NovaScan, a cancer detection technology developer, has entered a letter of intent with Epredia for the exclusive distribution of the MarginScan device in the US.
MarginScan is aimed at enhancing real-time detection of non-melanoma skin cancer.
Go deeper with GlobalData
The anticipated launch is set for next year, with the device expected to support physicians, particularly Mohs Micrographic surgeons, in identifying cancerous tissue with greater precision.
MarginScan will assist in Mohs surgery procedures, a technique used to treat skin cancer by excising cancerous tissue in stages and examining it until the margins are clear of the tumour.
Unlike traditional methods, MarginScan utilises electrical assessment to confirm cancer-free margins, potentially allowing for quicker and more tissue-conserving surgeries.
Skin cancer is the most diagnosed cancer globally, with non-melanoma skin cancers (NMSC) being the most prevalent in the US, affecting over three million Americans annually.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataWith the introduction of MarginScan, the aim is to improve surgical outcomes by reducing the amount of healthy tissue removed during excisions.
Epredia president Steven Lynum said: “With more than 85 years supporting precision cancer diagnostics, we strive to continuously serve the changing needs of our customers by working with innovative companies like NovaScan to deliver the best solutions.
“Helping providers make faster, more accurate diagnoses and ultimately improving patient care is what makes this initiative so important.”
NovaScan CEO Craig Davis said: “NovaScan is thrilled to be partnering with Epredia to bring MarginScan to clinical healthcare providers in the US. We are proud for MarginScan to join Epredia’s portfolio of market-leading cancer diagnostics products.
“We believe that MarginScan will play an important role in skin cancer detection and treatment.”
Precision cancer diagnostics developer Epredia will be the primary distributor of MarginScan in the US and will manage all marketing and commercial activities for the device.
The company has also partnered with Avantik to ensure that the device reaches Mohs Micrographic surgeons.
In addition to the device itself, Epredia will distribute consumables required for its operation, including the MarginScan electrode and a proprietary electrolytic gel.
In April 2023, Japanese healthcare company PHC partnered with NovaScan to explore the feasibility of the latter’s investigational medical device, MarginScan.
